Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space.
Klughammer J, Kiesel B, Roetzer T, Fortelny N, Nemc A, Nenning KH, Furtner J, Sheffield NC, Datlinger P, Peter N, Nowosielski M, Augustin M, Mischkulnig M, Ströbel T, Alpar D, Ergüner B, Senekowitsch M, Moser P, Freyschlag CF, Kerschbaumer J, Thomé C, Grams AE, Stockhammer G, Kitzwoegerer M, Oberndorfer S, Marhold F, Weis S, Trenkler J, Buchroithner J, Pichler J, Haybaeck J, Krassnig S, Mahdy Ali K, von Campe G, Payer F, Sherif C, Preiser J, Hauser T, Winkler PA, Kleindienst W, Würtz F, Brandner-Kokalj T, Stultschnig M, Schweiger S, Dieckmann K, Preusser M, Langs G, Baumann B, Knosp E, Widhalm G, Marosi C, Hainfellner JA, Woehrer A, Bock C. Klughammer J, et al. Among authors: krassnig s. Nat Med. 2018 Oct;24(10):1611-1624. doi: 10.1038/s41591-018-0156-x. Epub 2018 Aug 27. Nat Med. 2018. PMID: 30150718 Free PMC article.
A Profound Basic Characterization of eIFs in Gliomas: Identifying eIF3I and 4H as Potential Novel Target Candidates in Glioma Therapy.
Krassnig S, Wohlrab C, Golob-Schwarzl N, Raicht A, Schatz C, Birkl-Toeglhofer AM, Skofler C, Gantenbein N, Leoni M, Asslaber M, Leber SL, Mahdy-Ali K, von Campe G, Mayer M, Borenich A, Weis S, Benesch M, Haybaeck J. Krassnig S, et al. Cancers (Basel). 2021 Mar 23;13(6):1482. doi: 10.3390/cancers13061482. Cancers (Basel). 2021. PMID: 33807050 Free PMC article.
Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
Krassnig S, Leber SL, Orthmann A, Golob-Schwarzl N, Huber HJ, Wohlrab C, Skofler C, Pennauer M, Raicht A, Birkl-Toeglhofer AM, Naumann M, Mahdy-Ali K, von Campe G, Leoni M, Alcaniz J, Hoffmann J, Wälchli T, Weis S, Benesch M, Haybaeck J. Krassnig S, et al. J Neurooncol. 2023 Oct;165(1):91-100. doi: 10.1007/s11060-023-04451-y. Epub 2023 Oct 31. J Neurooncol. 2023. PMID: 37907716 Free PMC article.
Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.
Kleinegger F, Hofer E, Wodlej C, Golob-Schwarzl N, Birkl-Toeglhofer AM, Stallinger A, Petzold J, Orlova A, Krassnig S, Reihs R, Niedrist T, Mangge H, Park YN, Thalhammer M, Aigelsreiter A, Lax S, Garbers C, Fickert P, Rose-John S, Moriggl R, Rinner B, Haybaeck J. Kleinegger F, et al. Among authors: krassnig s. Biochim Biophys Acta Mol Basis Dis. 2019 Feb 1;1865(2):308-321. doi: 10.1016/j.bbadis.2018.11.006. Epub 2018 Nov 9. Biochim Biophys Acta Mol Basis Dis. 2019. PMID: 30419338 Free article.
Melanocytes, Organogenesis, and Angiogenesis: Evidence for More than a Pigment-Producing Capability of Melanocytes.
Schatz O, Zalaudek I, Ghaffari Tabrizi-Wizsy N, Grechenig C, Grinninger P, Haas A, Haybaeck J, Hofmann-Wellenhof R, Juch H, Krassnig S, Richtig E, Lackner A, Schwab K, Wedrich A, Weger M, Schwab C. Schatz O, et al. Among authors: krassnig s. Cells Tissues Organs. 2018;206(1-2):6-8. doi: 10.1159/000495908. Epub 2019 Jan 17. Cells Tissues Organs. 2018. PMID: 30654373 No abstract available.
Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures.
Alcaniz J, Winkler L, Dahlmann M, Becker M, Orthmann A, Haybaeck J, Krassnig S, Skofler C, Kratzsch T, Kuhn SA, Jödicke A, Linnebacher M, Fichtner I, Walther W, Hoffmann J. Alcaniz J, et al. Among authors: krassnig s. Front Oncol. 2023 Apr 11;13:1129627. doi: 10.3389/fonc.2023.1129627. eCollection 2023. Front Oncol. 2023. PMID: 37114125 Free PMC article.
Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression.
Gantenbein N, Bernhart E, Anders I, Golob-Schwarzl N, Krassnig S, Wodlej C, Brcic L, Lindenmann J, Fink-Neuboeck N, Gollowitsch F, Stacher-Priehse E, Asslaber M, Gogg-Kamerer M, Rolff J, Hoffmann J, Silvestri A, Regenbrecht C, Reinhard C, Pehserl AM, Pichler M, Sokolova O, Naumann M, Mitterer V, Pertschy B, Bergler H, Popper H, Sattler W, Haybaeck J. Gantenbein N, et al. Among authors: krassnig s. Eur J Cancer. 2018 Sep;101:165-180. doi: 10.1016/j.ejca.2018.07.001. Epub 2018 Aug 1. Eur J Cancer. 2018. PMID: 30077122 Free article.
Eukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma.
Skofler C, Kleinegger F, Krassnig S, Birkl-Toeglhofer AM, Singer G, Till H, Benesch M, Cencic R, Porco JA Jr, Pelletier J, Castellani C, Raicht A, Izycka-Swieszewska E, Czapiewski P, Haybaeck J. Skofler C, et al. Among authors: krassnig s. Cells. 2021 Feb 2;10(2):301. doi: 10.3390/cells10020301. Cells. 2021. PMID: 33540613 Free PMC article.
23 results